Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Rockwell Medical (RMTI) over the last 16 years, with Dec 2024 value amounting to $7.3 million.

  • Rockwell Medical's Cash from Financing Activities rose 191.57% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 112.45%. This contributed to the annual value of $7.3 million for FY2024, which is 35.21% down from last year.
  • Latest data reveals that Rockwell Medical reported Cash from Financing Activities of $7.3 million as of FY2024, which was down 35.21% from $11.3 million recorded in FY2023.
  • Rockwell Medical's Cash from Financing Activities' 5-year high stood at $63.3 million during FY2020, with a 5-year trough of -$2.2 million in FY2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $11.3 million (2023), whereas its average is $11.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 103.44% in 2021, then surged by 841.17% in 2022.
  • Yearly analysis of 5 years shows Rockwell Medical's Cash from Financing Activities stood at $63.3 million in 2020, then plummeted by 103.44% to -$2.2 million in 2021, then spiked by 841.17% to $16.1 million in 2022, then decreased by 29.77% to $11.3 million in 2023, then slumped by 35.21% to $7.3 million in 2024.